Haematological malignancies are a heterogeneous group of diseases with diverse incidence. In Europe, the median age at diagnosis across all disease entities is 69 years. Incidence generally increases with age, reaching a maximum at 75-99 years, with the notable exceptions of Hodgkin lymphoma and acute lymphocytic leukaemia. Overall survival for patients aged 75 years and older with haematological malignancies is generally poor, particularly for acute leukaemias. Understanding the heterogeneity in outcomes for haematological malignancies, treatment challenges, and management of frailty and comorbidities among older patients could help physicians to better address the haematological cancer burden and mortality in ageing populations. The aim of this Series paper is to provide an updated overview of the knowledge accumulated over the past decade regarding treatment options and broader management considerations in older adults with haematological malignancies, focusing on the most common entities encountered across lymphoma, acute leukaemia, chronic leukaemia, and multiple myeloma disease categories. Future strategies, such as increasing enrolment rates of older adults in clinical trials and incorporating patient-reported outcome measurements in daily clinical practice, will assist in providing more individualised health care.

中文翻译：

---

老年患者血液系统恶性肿瘤的综合治疗方法。

血液系统恶性肿瘤是一组具有不同发病率的异质性疾病。在欧洲，所有疾病实体的诊断年龄中位数为 69 岁。发病率通常随着年龄的增长而增加，在 75-99 岁时达到最大值，但霍奇金淋巴瘤和急性淋巴细胞白血病除外。75 岁及以上的血液系统恶性肿瘤患者的总生存率通常较差，尤其是急性白血病。了解血液系统恶性肿瘤结果的异质性、治疗挑战以及老年患者虚弱和合并症的管理可以帮助医生更好地解决老龄化人群的血液系统癌症负担和死亡率。本系列论文的目的是对过去十年积累的关于患有血液系统恶性肿瘤的老年人的治疗选择和更广泛的管理考虑事项的知识进行更新概述，重点关注淋巴瘤、急性白血病、慢性白血病、和多发性骨髓瘤疾病类别。未来的策略，例如提高老年人在临床试验中的参与率，以及将患者报告的结果测量纳入日常临床实践，将有助于提供更加个性化的医疗保健。